Rabies Vaccine Response End‑Point Titer (5789X)
Use
This test (also known as Rabies Virus Neutralizing Antibodies, RVNA) measures the neutralizing activity of rabies-specific antibodies using the Rapid Fluorescent Foci Inhibition Test (RFFIT). It assesses whether protective immunity has been achieved following vaccination by determining the endpoint titer (e.g., dilution titer or IU/mL), guiding decisions regarding booster doses and confirming immune response in individuals at occupational or exposure risk.
Special Instructions
Quest forwards testing to Kansas State Innovation Center (KSVDL).
Limitations
This assay uses a live-virus biological system with variability across reference serum titers per batch; results depend on calculation with the measured batch reference. Interpretation thresholds differ: ACIP considers complete neutralization at serum dilution of 1:5 (≈0.1 IU/mL) adequate, whereas WHO guideline is ≥0.5 IU/mL. The lower limit of accurate detection is 0.1 IU/mL.
Methodology
Other
Biomarkers
Result Turnaround Time
21-28 days
Related Documents
For more information, please review the documents below
Specimen
Serum
Volume
2‑4 mL
Minimum Volume
1 mL
Container
Red Top (No Additive)
Causes for Rejection
Gross hemolysis; Gross lipemia
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | Unacceptable |
| Refrigerated | 10 days |
| Frozen | 30 days |